Answers are grounded in this paper and cite their sources.
Substrate activity screening was used to rapidly identify a novel and potent (kinact/Ki=59 000 M−1 s−1) nonpeptidic chymotrypsin inhibitor with MW<500. The inhibitor is more potent than the best reported tetrapeptidyl phosphonate chymotrypsin inhibitor and demonstrated selectivity over a panel of other serine proteases, including the closely related enzyme cathepsin G.
No takes yet. Share an insight, caveat, or question.
Salisbury et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: